立体定向体部放疗联合同期顺铂再程放疗不可切除复发头颈部鳞状细胞癌的1期剂量递增研究
这项1期临床试验评估了再程放疗联合同期顺铂治疗既往放疗后局部区域复发头颈部鳞状细胞癌的最大耐受剂量。SBRT每2天一次共5次,起始剂量6 Gy×5次,递增至7 Gy×5次和8 Gy×5次,化疗为每次SBRT前给予顺铂15 mg/m2。20例入组、18例可评估,40 Gy剂量组未观察到剂量限制性毒性,结论认为SBRT剂量≤40 Gy联合同期顺铂安全可行。
要点
- SBRT每2天一次共5次,剂量从6 Gy×5次递增至8 Gy×5次,同期顺铂15 mg/m2每次SBRT前给药。
- 40 Gy剂量组9例未观察到剂量限制性毒性。
- 中位随访9.5个月,2年局部区域失败累积发生率61%,2年总生存率22%。
核心结论
- 同期顺铂联合SBRT剂量≤40 Gy再程放疗在局部区域复发或第二原发头颈部鳞状细胞癌患者中安全可行。
研究设计与样本
- 1期临床试验,入组既往放疗剂量≥45 Gy且距入组≥6个月、不适合手术或拒绝手术的复发头颈部鳞状细胞癌患者,SBRT每2天一次共5次,起始剂量6 Gy×5次,递增至7 Gy×5次和8 Gy×5次,化疗为每次SBRT前顺铂15 mg/m2,监测SBRT开始后3个月内发生的剂量限制性毒性,20例入组、18例可评估。
主要发现
- 剂量水平1(30 Gy)1例患者在治疗完成后2周不明原因死亡,该剂量组追加3例后未再观察到剂量限制性毒性。
- 剂量水平2(35 Gy)入组3例、剂量水平3(40 Gy)入组9例,均未观察到剂量限制性毒性。
- 中位随访9.5个月,2年局部区域失败累积发生率为61%(95%CI 12%-66%)。
- 2年远处转移累积发生率为11%(95%CI 74%-100%)。
- 2年总生存率为22%(95%CI 9%-53%)。
关键数值与推荐
- SBRT起始剂量水平为6 Gy×5次(30 Gy),随后为7 Gy×5次(35 Gy)和8 Gy×5次(40 Gy)。
- 顺铂剂量为每次SBRT前15 mg/m2。
- 剂量限制性毒性监测时间为SBRT开始后3个月内。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Patients with locoregional recurrence of squamous cell carcinoma of the head and neck (SCCHN) have relatively poor outcomes; therefore, stereotactic body radiation therapy (SBRT) has been investigated for this patient population. We performed a phase 1 clinical trial to establish a maximum tolerated dose of SBRT with concurrent cisplatin in previously irradiated locoregional SCCHN. METHODS AND MATERIALS: Patients with recurrent SCCHN who had previously undergone radiation therapy to doses ≥45 Gy to the area of recurrence ≥6 months before enrollment and who were not surgical candidates or refused surgery were eligible. SBRT was delivered every other day for 5 fractions. Starting dose level was 6 Gy × 5 fractions, followed by 7 Gy × 5 fractions and 8 Gy × 5 fractions. Chemotherapy consisted of cisplatin given before every SBRT fraction at a dose of 15 mg/m2. Patients were monitored for dose-limiting toxicities (DLT) that occurred within 3 months from the start of SBRT. Secondary endpoints included locoregional failure, distant metastasis, and overall survival. RESULTS: Twenty patients were enrolled, with 18 patients evaluable for endpoints. One patient at dose level 1 (30 Gy) died of unknown causes 2 weeks following completion of treatment. Therefore, an additional 3 patients were accrued to the 30-Gy dose level, with no further DLTs observed. Three patients were then accrued at dose level 2 (35 Gy) and 9 patients at dose level 3 (40 Gy) without DLTs. At a median follow-up of 9.5 months, cumulative incidence of locoregional failure at 2 years was 61% (95% confidence interval [CI], 12%-66%), cumulative incidence of distant metastasis was 11% (95% CI, 74%-100%) at 2 years, and overall survival was 22% (95% CI, 9%-53%) at 2 years. CONCLUSIONS: Concurrent cisplatin and reirradiation with an SBRT dose of ≤40 Gy was safe and feasible in patients with locoregionally recurrent or second primary SCCHN.
引用
- Echevarria MI, Yang GQ, Chen DT, et al. Phase 1 Dose Escalation of Stereotactic Body Radiation Therapy and Concurrent Cisplatin for Reirradiation of Unresectable, Recurrent Squamous Cell Carcinoma of the Head and Neck. Int J Radiat Oncol Biol Phys. 2023. PMID: 37105404. doi:10.1016/j.ijrobp.2023.04.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。